top of page
Untitled design (5).png

OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY

start
16.png
23.png
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology.  Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)…. 
about
 Everads News

September 2024

Everads wins startup competition at the Eye and Beyond II Conference

Everads is excited to announce that it was selected as the top startup at the Eye and Beyond II conference hosted by the Ophthalmology Division of the Rabin Medical Center. The Eye & Beyond ophthalmic conference is a bi annual conference for innovation in ophthalmology. The presentation, delivered by Keren Mano Tamir, MD, Head of Scientific Strategy at Everads was recognized as the most promising ophthalmic startup for 2024.

The eye and beyond team.jpg

May 2024

2 Posters at ARVO show AAV-GFP Transduction to Macular RPE and Past Posterior Pole in NHP Achieved with Everads Delivery Technology

Everads is excited to announce the presentation of two posters at ARVO 2024 featuring results in non-human primates using Everads suprachoroidal delivery technology. Eclov et al reported achieving circumferential transduction past the posterior pole using AAV2 after suprachoroidal injection in NHPs and Barak et al demonstrated the delivery of AAV5-GFP to the Macular RPE.

 

Access the abstracts/posters here: Eclov et al  and Barak et al

arvo 2024.jpg

September 2024

Everads Leads Suprachoroidal Workshop at Gene Therapy for Ophthalmic Disorders Summit

Everads therapy CEO, Moshe Weinstein, and Head of Scientific Strategy, Dr. Keren Mano Tamir, co lead the suprachoroidal innovations pre-conference workshop at the 5th Annual Gene Therapy for Ophthalmic Disorders Conference in Boston. The session was co-lead by Rachel Eclov, Sr. Director, Opthalmology, of Kriya Therapeutics. The workshop provided a dead-dive into suprachoroidal delivery for gene therapy, including a review of suprachoroidal delivery and various delivery technologies, preclinical considerations for device and capsid and clinical updates from Everads first in human clinical trial.

Gene Therapy for Ophtalmic disorders summit 2.jpg

September 2023

Everads enters license agreement with Kriya Therapeutics for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology.

For Kriya's press release click here

For Everads' press release click here

Shutterstock_1946757709.jpg

September 2024

Everads Presents Clinical Data from First-in-Human Trial of Suprachoroidal Delivery Technology at EURETINA

Presentation : Everads Therapy

EUretina.jpg

June 2023

Everads is pleased to announce the publication in Translation Vision Sciences & Technology (TVST), an ARVO journal, of data showing that Everads’ suprachoroidal delivery technology enables safe, rapid and broad delivery throughout the posterior pole in non-human primate models. This work demonstrated that Everads’ technology was able to deliver 150-200 µL of ICG dye to the back of the eye via the suprachoroidal space. The injection was well tolerated in NHP eyes, with rapid distribution into the macular region and throughout the posterior pole. Moshe Weinstein, CEO of Everads, stated that “we are honored to have such a prestigious journal publish this promising data. Demonstrating the efficacy of this technology in non-human primates further confirms the promising results that can be achieved with our technology and we look forward to continuing its development with our collaborators”.

tvst 5_edited.jpg
NEWS HOME
cntact form
Contact Us

Send us a message and we’ll get back to you shortly.

Thanks for submitting!

bottom of page